by Lori Solomon
Si-Qi Li, from the Peking University People’s Hospital in Beijing, and colleagues assessed the ability of the LSC-based method and the traditional multiparameter flow cytometry (MFC) assay to predict leukemia relapse after long-term follow-up. The analysis included 360 patients with AML who received allografts between July 2018 and November 2019.
The researchers found that patients with positive MRD based on CD34+CD38−cocktail+ LSCs (≥0.004%) had a greater five-year cumulative incidence of relapse (CIR; 49.7 versus 8.5%), inferior leukemia-free survival (LFS; 48.2 versus 84.4%), and inferior overall survival (OS; 59.7 versus 82.8%) versus patients without CD34+CD38−cocktail+ LSCs (<0.004%).
Patients with detectable traditional MFC-MRD also had a greater CIR than patients without MRD (45.8 versus 10.9%), resulting in decreased LFS (54.2 versus 81.9%) and decreased OS (56.0 versus 85.9%). The LSC-based MRD assay had good performance, with high sensitivity (52.4 versus 33.3%), a high C-index (0.72 versus 0.65), and high Youden index (0.44 versus. 0.27), compared with traditional MFC-MRD. The median time from LSC positivity to relapse was longer compared with traditional MRD positivity to relapse (144 versus 65 days).
“The results reported by other researchers and from our long-term follow-up study provide further evidence that the LSC-based MRD assay should be recommended for relapse prediction in patients with AML,” the authors write.
More information: Si-Qi Li et al, Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study, Bone Marrow Transplantation (2025). DOI: 10.1038/s41409-025-02699-8
© 2025 HealthDay. All rights reserved.
Explore further
Worse overall survival seen for adults with leukemia with CNS involvement
